Inflammatory Conditions - Tocilizumab Intravenous Products Utilization Management
Customize your policy alerts
Sign up for all Aspirus Arise policy alerts
Know when Aspirus Arise releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization and coverage criteria for intravenous tocilizumab products (Actemra, Avtozma, Tofidence) for Aspirus Medicare Plans, including indication- and dosing-based authorization rules and preferred product step therapy.
Updated policy statement to indicate that the acute treatment of COVID-19 in hospitalized patients is not addressed in this policy.
UCare added a preferred biosimilar step with Tyenne as the preferred biosimilar before Actemra and Tofidence for patients new to therapy effective 1/1/2025.
Condition-specific age requirements were added for initial approvals across multiple indications (e.g., ≥18 for giant cell arteritis, RA initial approvals, polymyalgia rheumatica; ≥2 for SJIA and polyarticular JIA).
Tyenne (biosimilar to Actemra Intravenous) was added to the policy with the same criteria as Actemra Intravenous.
Policy renamed to Inflammatory Conditions - Tocilizumab Intravenous Products and wording changed from Actemra to tocilizumab throughout the policy.
Tofidence intravenous was added to the policy with the same criteria as other tocilizumab intravenous products.
Giant cell arteritis and several other indications now include explicit minimum age requirements (e.g., ≥18 years for multiple conditions; ≥2 years for polyarticular juvenile idiopathic arthritis).
Updated step therapy to require clinical need for non-preferred product over preferred products, including chart note documentation to support the need.
Selected revisions added or clarified indications and examples (e.g., CAR T-cell therapies examples, AOSD/SJIA alignment, biosimilar counting rules).
Coverage Criteria and Indication-specific Rules
Cytokine Release Syndrome (CAR T-cell therapy)
Approve when BOTH dosing and duration conditions are met
Approve for 1 week duration (adequate to receive four doses)
Giant Cell Arteritis
Approve when ONE of the following initial or continuation pathways is met
Example corticosteroid: prednisone
Dosing: up to 6 mg/kg to maximum 600 mg per dose; interval at least 4 weeks between doses.
Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Approve when ONE of the following initial or continuation pathways is met
A biologic counts as a trial of one systemic therapy; examples of absolute contraindications to methotrexate include pregnancy, breastfeeding, alcoholic liver disease, immunodeficiency, blood dyscrasias.
Dosing: <30 kg: up to 10 mg/kg to a maximum of 800 mg per dose; ≥30 kg: up to 8 mg/kg to a maximum of 800 mg per dose; interval ≥ 4 weeks between doses.
Rheumatoid Arthritis
Approve when ONE of the following initial or continuation pathways is met
A patient who has already tried a biologic is not required to 'step back' to a conventional DMARD.
Dosing: up to 8 mg/kg to a maximum of 800 mg per dose with an interval of at least 4 weeks between doses.
Indication-specific approval criteria (selected)
Coverage is allowed when indication-specific AND/OR criteria are met; initial approvals often require age and prescriber requirements plus prior therapy trials; continuation approvals require established therapy duration and evidence of benefit.
Refer to indication-specific dosing limits and intervals
Examples of objective measures provided in policy
SJIA and AOSD are considered the same disease differing by age of onset
Objective measures examples include CRP, ESR, fibrinogen, albumin, hemoglobin, BMI, reduction in lymphadenopathy
Examples of bispecific antibodies provided in policy
Examples of systemic medications provided
Objective measures depend on organ involvement
Objective measures include CRP, ESR, resolution of fever, or corticosteroid reduction
AOSD and SJIA considered same disease differing by age
Objective measures examples include resolution of fever, skin improvement, CRP/ESR normalization, corticosteroid reduction
Policy-level coverage updates
Policy-level coverage criteria updates and notes
Chart note documentation required to justify bypass of preferred biosimilar
Applies to initial approvals as specified per indication
See full policy for complete indication-level criteria and history
The policy does not address the acute treatment of COVID-19 in hospitalized patients. Prior authorization is recommended for tocilizumab intravenous products overall, but any requests for tocilizumab used specifically as acute therapy for hospitalized COVID-19 patients fall outside the scope of this policy and should be managed per institutional protocols or relevant COVID-19–specific guidance.
Coverage of tocilizumab intravenous products is not recommended for COVID-19 except for the narrow hospitalized adult indication described in product labeling (hospitalized adults receiving systemic corticosteroids who require supplemental oxygen, non‑invasive or invasive ventilation, or ECMO). The policy also lists concurrent use with another biologic or with a targeted synthetic oral small molecule drug for inflammatory conditions as not recommended. Requests for uses not listed in the Recommended Authorization Criteria (for example, Crohn's disease) are likewise not recommended without stronger evidence.
Wording for COVID-19 exclusions was revised to clarify that the policy excludes the acute treatment of COVID-19 in hospitalized patients from its coverage guidance. Operationally, the policy also updated corticosteroid trial language (now requiring the patient has tried or is currently taking a systemic corticosteroid unless contraindicated) where relevant to indications that reference corticosteroid use.
Coverage for tocilizumab intravenous products is not recommended for Crohn's disease at this time. The policy cites a single 12‑week pilot study with limited sample size and inconclusive results and therefore deems the current evidence insufficient to support routine approval for this indication.
The policy specifies that concurrent administration of tocilizumab with another biologic or with a targeted synthetic oral small molecule drug for inflammatory conditions is not recommended and may trigger denial of authorization. This concurrent use exclusion was highlighted in the history as a clarified policy-level change and remains a common denial trigger.
| affected codes | policy references dosing and product-specific rules; exact billing codes not present in this excerpt |
Dosing, Age Limits, and Code References
| Actemra | Tocilizumab intravenous product (Actemra) |
| Tyenne | Tyenne (biosimilar to Actemra Intravenous) |
| Tofidence | Tofidence intravenous tocilizumab product |
| Avtozma | Avtozma (tocilizumab intravenous product) |
Prior Authorization, Step Therapy, and Documentation Requirements
Prior Authorization Required — Indication-Specific and Age-Based Criteria
Prior Authorization is recommended for medical benefit coverage of tocilizumab intravenous products. Approval is recommended only when patients meet indication-specific criteria (age, prior therapies, prescriber specialty, and demonstrated clinical response or symptom improvement) as detailed in the FDA-Approved Indications and Other Uses sections. Initial approvals require the medication to be prescribed by or in consultation with a physician who specializes in the condition being treated. Initial age requirements apply for multiple indications (e.g., ≥18 years for many adult indications; ≥2 years for polyarticular juvenile idiopathic arthritis and other pediatric-specific indications).
- Prior authorization applies to Actemra, Avtozma, and Tofidence (Tyenne is the preferred product)
- Initial approvals require prescriber specialty consultation (physician who specializes in the condition)
- Indication-specific age requirements must be met for initial approvals (see policy indication details)
Preferred Biosimilar Step Therapy for New-to-Therapy Patients
A preferred biosimilar (Tyenne) is required as the first-line product for patients who are new to therapy effective 01/01/2025. For patients new to therapy, authorization for non-preferred products (Actemra, Avtozma, Tofidence) will be granted only if the patient meets one of the step therapy exceptions or documents clinical need. For patients who are not new to the requested non-preferred product (used within prior 365 days), the step does not apply.
- Effective 01/01/2025: Tyenne is the preferred biosimilar for new-to-therapy patients
- Non-preferred products: Actemra, Avtozma, Tofidence
- New-to-therapy defined as no use of the requested product in the previous 365 days
Preferred Product Step Therapy — Exceptions and Required Documentation
Authorization for a non-preferred biologic product or biosimilar will be granted only if the patient meets at least one of the listed exceptions. Chart notes documenting the applicable exception must be provided at the time of request. Factors such as patient or prescriber preference or inability to stock the preferred product will not be accepted as exceptions. Common side effects or infusion-related reactions do not qualify as documented allergic reactions.
- Exceptions that permit approval of a non-preferred product (one of A–E must be met and documented):
- A. Patient is not a new start to the non-preferred product (used within prior 365 days)
- B. Allergic reaction to a specific inactive ingredient in all preferred products or biosimilars
- C. Adverse reaction to a specific inactive ingredient in all preferred products or biosimilars
- D. Therapeutic success on the non-preferred product AND therapeutic failure on an adequate trial of all preferred products (adequate trial generally ≥3 months)
- E. Patient has a diagnosis included in the non-preferred product’s FDA indications but not included in the preferred products’ FDA indications
Required Documentation at Time of Request
At the time of request, submit chart notes documenting prior trials, allergic or adverse reactions to preferred products, contraindications, therapeutic failure, and baseline status. Documentation must support clinical need for a non-preferred product over the preferred biosimilar for new-to-therapy patients; failure to provide appropriate chart documentation may result in denial.
- Chart notes must document: prior medication trials and durations, objective measures or symptom changes from baseline, specific allergic/adverse reactions or contraindications, and rationale for selecting a non-preferred product
- For new-to-therapy patients, document why Tyenne (preferred biosimilar) is not appropriate or acceptable
Clinical Response and Prescriber Documentation Requirements
For continuation/established therapy, requests must document clinical response versus baseline using at least one objective measure or demonstrable symptom improvement (examples include disease activity scores, physician/patient global assessments, and relevant serum markers). Documentation should indicate duration of prior therapy (established on therapy ≥6 months for some indications) and meet any specialty prescriber requirements noted in the indication-specific criteria.
- Acceptable objective measures: CDAI, DAS28 (ESR/CRP), RAPID-3, SDAI, JADAS, cJADAS, CRP/ESR, Physician/Patient Global Assessments
- For continuation approvals: patient established on therapy ≥6 months for some indications; demonstrate beneficial clinical response or symptom improvement from baseline
Background and Scope
Tocilizumab is an interleukin‑6 (IL‑6) receptor inhibitor used to treat multiple inflammatory conditions, including cytokine release syndrome (CRS) related to CAR T‑cell therapy, giant cell arteritis, systemic and polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis. Dosing and monitoring are indication‑specific and include weight‑based dose rules and laboratory‑guided dose interruption/modification for abnormalities.
Definitions, Dosing Guidance, and Abbreviations
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.